Press Release
Our company's new compound drug NDF01 for the treatment of HIV infection has been approved by the Ministry of Health and Welfare
Our company's new compound drug NDF01 for the treatment of HIV infection was approved and obtained the drug license, and we received the approval letter on January 8, 2025.
Based on the announcement from the Ministry of Health and Welfare (Health Food No. 1120726627).
This product is a new compound new drug:
A. Certification number: Ministry of Health Pharmaceutical Factory No. 061903.
B. Chinese and English product name: AidzPir Film Coated Tablets.
C. Indications: For patients with type 1 virus who are over 12 years old and weigh at least 35 kg and have not previously received antiretroviral therapy and are treated with a combination of efavirenz, lamivudine and tenofovir. Immunodeficiency virus (HIV-1) infected patients who do not have a mutation known to confer resistance to the fifth component of this product.
Brazil's INPI Approves Patent for Our Single-Chain Immunoglobulin Fusion Protein Technology Platform.
Our proprietary Single-Chain Immunoglobulin Fusion Protein Technology Platform has been officially granted a patent by the Brazilian National Institute of Industrial Property (INPI) (Patent No.: BR 112017026713-6).
This innovative technology has secured patents across multiple global jurisdictions, including Taiwan, the United States, the European Union, Japan, Canada, Australia, New Zealand, China, India, Malaysia, Hong Kong, Singapore, and South Korea.
The platform is utilized in the development of our products, such as UB-551 and UB-853.